Clinical trial · Observational
Efficacy and Safety of Plastic, Covered and Uncovered Self-expandable Metal Stents in the Treatment of Malignant Biliary Obstructions (NEOSTENT)
NCT05395013CI-TRIAL-00058940NEOSTENTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to evaluate the efficacy and safety of the various types of stents available for biliary drainage in patients with neoplastic stenosis of the common bile duct and to evaluate the adherence to the current guidelines available.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Common Bile Duct Stricture | — | UNRESOLVED | — |
| Jaundice; Malignant | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Bilirubin decrease
- timeFrame
- From 2017 to 2021
- description
- Rate of resolution of obstructive jaundice in short and long term (i.e. maintenance of patency and/or the need for reintervention) of the different types of biliary stent placed in patients with neoplastic stenosis of the common bile duct
Secondary outcomes (3)
- measure
- Rate of adverse events
- timeFrame
- From 2017 to 2021
- description
- Rate of periprocedural complications (i.e. bleeding, pancreatitis, cholecystitis) after biliary stent placement
- measure
- Rate of endoscopic reintervention
- timeFrame
- From 2017 to 2021
- description
- Rate of stent disfunction requiring an additional endoscopic procedure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Common bile duct stricture (i.e. jaundice and/or cholangitis) of malignant origin * Patients \> 18 years old * Obtaining informed consent Exclusion Criteria: \- Lack of sufficient clinical and laboratory data to define clinical efficacy and/or follow-up available \<1 month
References
Publications (0)
Data not yet available
No reference posted for this study.